Literature DB >> 30386911

Prediction of mizoribine pharmacokinetic parameters by serum creatinine in renal transplant recipients.

Pan Chen1, Xuan Xu1, Longshan Liu2, Jingjing Wu1, Jingjie Li3, Qian Fu2, Jie Chen4, Changxi Wang5.   

Abstract

PURPOSE: Mizoribine (MZR) is an immunosuppressive agent with extensive inter-individual differences in pharmacokinetics (PK). Here, we investigated the PK characteristics of MZR in renal transplant recipients and gave equations for prediction of some critical PK parameters.
METHODS: A total of 40 renal transplant recipients participated in this prospective study and were administered MZR orally twice daily in the range of 1.1-8.9 mg kg-1 day-1. Steady-state concentrations of MZR were detected before (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, and 12 h after administration by high-performance liquid chromatography method. Another 38 patients with newly detected trough concentration (C0) were enrolled to validate the obtained C0 predictive equation.
RESULTS: Significant inter-individual differences in MZR PK parameters were observed. Patients with decreasing creatinine clearance rate (CCr) had significantly decreased terminal elimination rate constant (kel) and apparent total body clearance (Cl/F), while other PK parameters including apparent terminal half-life (t1/2), peak time (Tmax), peak concentration (Cmax), area under the curve (AUC0-12h), apparent volume of distribution (V/F), and mean residence time (MRT) were significantly increased. Correlation coefficients between AUC0-12h and C0/Cmax were 0.894 and 0.916, respectively (both p < 0.001). A serum creatinine (SCr)-based predictive C0 equation [C0 = (2.160 × SCr - 54.473) × Dose] was established and validated by C0 from another 38 patients. Besides, significant linear correlations between kel/t1/2 and CCr were also found (r2 = 0.668 and 0.484, respectively), and equations predicting kel/t1/2 were also obtained (kel = 0.015 + 0.002 × CCr, t1/2 = 13.601 - 0.139 × CCr).
CONCLUSIONS: Renal function plays as an essential factor that contributes to great inter-individual MZR PK variation. Both C0 and Cmax are suitable for evaluating MZR exposure in the body. SCr could be applied to predict C0 and t1/2 of MZR.

Entities:  

Keywords:  Immunosuppression; Mizoribine; Pharmacokinetics; Renal transplantation

Mesh:

Substances:

Year:  2018        PMID: 30386911     DOI: 10.1007/s00228-018-2584-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Clinical pharmacokinetic study of mizoribine in renal transplantation patients.

Authors:  K Sonda; K Takahashi; K Tanabe; S Funchinoue; Y Hayasaka; H Kawaguchi; S Teraoka; H Toma; K Ota
Journal:  Transplant Proc       Date:  1996-12       Impact factor: 1.066

2.  Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males.

Authors:  Miki Fukao; Kazuya Ishida; Takuya Sakamoto; Masato Taguchi; Hiroyoshi Matsukura; Toshio Miyawaki; Yukiya Hashimoto
Journal:  Drug Metab Pharmacokinet       Date:  2011-07-05       Impact factor: 3.614

3.  Effect of salt intake on bioavailability of mizoribine in healthy Japanese males.

Authors:  Kazuya Ishida; Miki Fukao; Hitomi Watanabe; Masato Taguchi; Toshio Miyawaki; Hiroyoshi Matsukura; Osamu Uemura; Zufei Zhang; Jashvant D Unadkat; Yukiya Hashimoto
Journal:  Drug Metab Pharmacokinet       Date:  2012-07-17       Impact factor: 3.614

4.  The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease.

Authors:  Takuhito Nagai; Osamu Uemura; Hisashi Kaneda; Katsumi Ushijima; Kazuhide Ohta; Yoshimitsu Gotoh; Kenichi Satomura; Masaki Shimizu; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2016-11-21       Impact factor: 2.801

5.  Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection.

Authors:  DaGe Liu; Takaaki Kobayashi; Takaharu Nagasaka; Itsuo Yokoyama; Yu Ma; Yuko Miwa; Takafumi Kuzuya; Kunio Morozumi; Tadashi Oikawa; Yasunobu Shimano; Oki Takeuchi; Kazuharu Uchida; Akimasa Nakao
Journal:  Transpl Int       Date:  2005-04       Impact factor: 3.782

6.  Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China.

Authors:  Y Shi; H Liu; X-G Chen; Z-Y Shen
Journal:  Transplant Proc       Date:  2017 Jan - Feb       Impact factor: 1.066

Review 7.  Mizoribine: mode of action and effects in clinical use.

Authors:  Shumpei Yokota
Journal:  Pediatr Int       Date:  2002-04       Impact factor: 1.524

8.  Mizoribine requires individual dosing due to variation of bioavailability.

Authors:  Toshiya Fuke; Yoshifusa Abe; Satoshi Hibino; Mikawa Takeshi; Takako Saito; Shunsuke Sakurai; Shuichiro Watanabe; Jun-ichiro Murayama; Kazuo Itabashi; Yasuko Nakano
Journal:  Pediatr Int       Date:  2012-12       Impact factor: 1.524

9.  Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation--a meta-analysis.

Authors:  Shuai Xing; Jun Yang; Xue Zhang; Ping Zhou
Journal:  Clin Biochem       Date:  2014-01-24       Impact factor: 3.281

10.  Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients.

Authors:  Takafumi Naito; Shunsuke Tokashiki; Yasuaki Mino; Atsushi Otsuka; Seiichiro Ozono; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-11-11       Impact factor: 4.080

View more
  2 in total

1.  Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients.

Authors:  Rui Dai; Jingjie Li; Jingjing Wu; Qian Fu; Jiajia Yan; Guoping Zhong; Changxi Wang; Xiao Chen; Pan Chen
Journal:  Eur J Clin Pharmacol       Date:  2020-08-15       Impact factor: 2.953

2.  Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report.

Authors:  Yohan Park; Byung Ha Chung; Cheol Whee Park; Yong-Soo Kim; Chul Woo Yang
Journal:  BMC Nephrol       Date:  2020-07-02       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.